Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
Phase II Study of Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 (Excision Repair Cross-complementation Group 1)
Status: Enrolling
Updated:  1/30/2012
Univ of Hawaii
mi
from
Honolulu, HI
Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
Phase II Study of Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 (Excision Repair Cross-complementation Group 1)
Status: Enrolling
Updated: 1/30/2012
Univ of Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
A Therapeutic Trial of Afatinib in the Neoadjuvant Setting. Molecular Effects of Afatinib: A Window of Opportunity Trial In Early Stage NSCLC
Status: Enrolling
Updated:  1/31/2012
Medical University of South Carolina
mi
from
Charleston, SC
A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
A Therapeutic Trial of Afatinib in the Neoadjuvant Setting. Molecular Effects of Afatinib: A Window of Opportunity Trial In Early Stage NSCLC
Status: Enrolling
Updated: 1/31/2012
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer
Status: Enrolling
Updated:  2/1/2012
University of Tennessee Cancer Institute
mi
from
Knoxville, TN
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer
Status: Enrolling
Updated: 2/1/2012
University of Tennessee Cancer Institute
mi
from
Knoxville, TN
Click here to add this to my saved trials
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer
Status: Enrolling
Updated:  2/1/2012
The West Clinic, PC
mi
from
Memphis, TN
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer
Status: Enrolling
Updated: 2/1/2012
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer
Status: Enrolling
Updated:  2/1/2012
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer
Status: Enrolling
Updated: 2/1/2012
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
A Pilot Study to Assess the Technical Feasibility of Robotic Assisted Laparoscopic Interpositioning of the AVANCETM Nerve Graft for Reconstruction of the Neurovascular Bundle, With a Twenty-four Month Follow-up Term to Assess Efficacy
Status: Enrolling
Updated:  2/1/2012
Vanderbilt University
mi
from
Nashville, TN
Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
A Pilot Study to Assess the Technical Feasibility of Robotic Assisted Laparoscopic Interpositioning of the AVANCETM Nerve Graft for Reconstruction of the Neurovascular Bundle, With a Twenty-four Month Follow-up Term to Assess Efficacy
Status: Enrolling
Updated: 2/1/2012
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer
A Phase 2 Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer
Status: Enrolling
Updated:  2/6/2012
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer
A Phase 2 Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer
Status: Enrolling
Updated: 2/6/2012
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Breast Cancer Risk Biomarkers in Premenopausal Women
Modulation of Breast Cancer Risk Biomarkers in Premenopausal Women by High Dose Omega-3 Fatty Acids
Status: Enrolling
Updated:  2/6/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
Breast Cancer Risk Biomarkers in Premenopausal Women
Modulation of Breast Cancer Risk Biomarkers in Premenopausal Women by High Dose Omega-3 Fatty Acids
Status: Enrolling
Updated: 2/6/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Diet Composition, Weight Control, and Breast Carcinogenesis
Diet Composition, Weight Control, and Breast Carcinogenesis
Status: Enrolling
Updated:  2/9/2012
Rocky Mountain Cancer Center
mi
from
Denver, CO
Diet Composition, Weight Control, and Breast Carcinogenesis
Diet Composition, Weight Control, and Breast Carcinogenesis
Status: Enrolling
Updated: 2/9/2012
Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Acceptance of Human Papillomavirus Vaccination in Postpartum Women
Acceptance of Human Papillomavirus Vaccination in Postpartum Women
Status: Enrolling
Updated:  2/13/2012
Columbia University Medical Center
mi
from
New York, NY
Acceptance of Human Papillomavirus Vaccination in Postpartum Women
Acceptance of Human Papillomavirus Vaccination in Postpartum Women
Status: Enrolling
Updated: 2/13/2012
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection
MRI With Secretin Enhancement to Increase Conspicuity of Pancreatic Cancer
Status: Enrolling
Updated:  2/14/2012
Columbia University Medical Center
mi
from
New York, NY
Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection
MRI With Secretin Enhancement to Increase Conspicuity of Pancreatic Cancer
Status: Enrolling
Updated: 2/14/2012
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
An Intervention Study To Improve HPV Immunization in Haitian and African American Girls
A Randomized Clinical Trial To Improve HPV Immunization in Haitian and African American Girls
Status: Enrolling
Updated:  2/21/2012
Boston Med Center
mi
from
Boston, MA
An Intervention Study To Improve HPV Immunization in Haitian and African American Girls
A Randomized Clinical Trial To Improve HPV Immunization in Haitian and African American Girls
Status: Enrolling
Updated: 2/21/2012
Boston Med Center
mi
from
Boston, MA
Click here to add this to my saved trials
Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Detectable Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  2/22/2012
Mayo Clinic
mi
from
Jacksonville, FL
Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Detectable Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 2/22/2012
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Psychosocial Benefits of Exercise in Endometrial Cancer Survivors
Psychosocial Benefits of Exercise in Endometrial Cancer Survivors
Status: Enrolling
Updated:  2/24/2012
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Psychosocial Benefits of Exercise in Endometrial Cancer Survivors
Psychosocial Benefits of Exercise in Endometrial Cancer Survivors
Status: Enrolling
Updated: 2/24/2012
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Real-Time Near-infrared (NIR) Mapping of Sentinel Lymph Nodes in Breast Cancer
Phase II Real-Time NIR-Guided Sentinel Lymph Node Mapping in Breast Cancer
Status: Enrolling
Updated:  2/24/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Real-Time Near-infrared (NIR) Mapping of Sentinel Lymph Nodes in Breast Cancer
Phase II Real-Time NIR-Guided Sentinel Lymph Node Mapping in Breast Cancer
Status: Enrolling
Updated: 2/24/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
Hematology Oncology P.C.
mi
from
Stamford, CT
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
Hematology Oncology P.C.
mi
from
Stamford, CT
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
Central Georgia Cancer Care
mi
from
Macon, GA
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
Central Georgia Cancer Care
mi
from
Macon, GA
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
North Shore Cancer Research
mi
from
Skokie, IL
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
North Shore Cancer Research
mi
from
Skokie, IL
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
Baystate Medical Center
mi
from
Springfield, MA
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
Baystate Medical Center
mi
from
Springfield, MA
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
Hematology-Oncology Centers of the Northern Rockies - Billings
mi
from
Billings, MT
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
Hematology-Oncology Centers of the Northern Rockies - Billings
mi
from
Billings, MT
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
Oncology Hematology Specialists, P.A.
mi
from
Denville, NJ
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
Oncology Hematology Specialists, P.A.
mi
from
Denville, NJ
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
The Moses H. Cone Regional Cancer Center
mi
from
Greensboro, NC
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
The Moses H. Cone Regional Cancer Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
North Coast Cancer Care
mi
from
Sandusky, OH
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
North Coast Cancer Care
mi
from
Sandusky, OH
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
The West Clinic, PC
mi
from
Memphis, TN
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
University of Tennessee Cancer Institute
mi
from
Knoxville, TN
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
University of Tennessee Cancer Institute
mi
from
Knoxville, TN
Click here to add this to my saved trials
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated:  2/27/2012
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: Enrolling
Updated: 2/27/2012
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Status: Enrolling
Updated:  3/1/2012
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Status: Enrolling
Updated: 3/1/2012
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Status: Enrolling
Updated:  3/1/2012
NSABP Foundation, Inc.
mi
from
Pittsburgh, PA
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Status: Enrolling
Updated: 3/1/2012
NSABP Foundation, Inc.
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Status: Enrolling
Updated:  3/1/2012
University of Pittsburgh
mi
from
Pittsburgh, PA
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Status: Enrolling
Updated: 3/1/2012
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Status: Enrolling
Updated:  3/1/2012
West Virginia University Hospitals
mi
from
Morgantown, WV
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Status: Enrolling
Updated: 3/1/2012
West Virginia University Hospitals
mi
from
Morgantown, WV
Click here to add this to my saved trials
Bladder Cancer Imaging Study-OCT Imaging to Stage Bladder Tumors
Optical Coherence Tomography as an Adjunct to White Light Cystoscopy for Intravesical Real Time Imaging and Staging of Bladder Cancer
Status: Enrolling
Updated:  3/7/2012
Baylor College of Medicne
mi
from
Houston, TX
Bladder Cancer Imaging Study-OCT Imaging to Stage Bladder Tumors
Optical Coherence Tomography as an Adjunct to White Light Cystoscopy for Intravesical Real Time Imaging and Staging of Bladder Cancer
Status: Enrolling
Updated: 3/7/2012
Baylor College of Medicne
mi
from
Houston, TX
Click here to add this to my saved trials
Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck
A Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of the Head and Neck
Status: Archived
Updated:  3/7/2012
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck
A Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of the Head and Neck
Status: Archived
Updated: 3/7/2012
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Collection of FUJIFILM's 3Dimensional Mammograms
Acquisition of Mammography Images for Clinical Evaluation of FUJIFILM 3Dimensional Mammography
Status: Enrolling
Updated:  3/9/2012
Scottsdale Medical Imaging, Limited (SMIL)
mi
from
Scottsdale, AZ
Collection of FUJIFILM's 3Dimensional Mammograms
Acquisition of Mammography Images for Clinical Evaluation of FUJIFILM 3Dimensional Mammography
Status: Enrolling
Updated: 3/9/2012
Scottsdale Medical Imaging, Limited (SMIL)
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Collection of FUJIFILM's 3Dimensional Mammograms
Acquisition of Mammography Images for Clinical Evaluation of FUJIFILM 3Dimensional Mammography
Status: Enrolling
Updated:  3/9/2012
Emory University Healthcare
mi
from
Atlanta, GA
Collection of FUJIFILM's 3Dimensional Mammograms
Acquisition of Mammography Images for Clinical Evaluation of FUJIFILM 3Dimensional Mammography
Status: Enrolling
Updated: 3/9/2012
Emory University Healthcare
mi
from
Atlanta, GA
Click here to add this to my saved trials
Collection of FUJIFILM's 3Dimensional Mammograms
Acquisition of Mammography Images for Clinical Evaluation of FUJIFILM 3Dimensional Mammography
Status: Enrolling
Updated:  3/9/2012
Elizabeth Wende Breast Care, LLC (EWBC)
mi
from
Rochester, NY
Collection of FUJIFILM's 3Dimensional Mammograms
Acquisition of Mammography Images for Clinical Evaluation of FUJIFILM 3Dimensional Mammography
Status: Enrolling
Updated: 3/9/2012
Elizabeth Wende Breast Care, LLC (EWBC)
mi
from
Rochester, NY
Click here to add this to my saved trials
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
Pharmacodynamic Study Using FLT-PET/CT in Patients With Prostate and Other Solid Malignancies Treated With an Interrupted High-dose Axitinib Schedule
Status: Enrolling
Updated:  3/12/2012
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
Pharmacodynamic Study Using FLT-PET/CT in Patients With Prostate and Other Solid Malignancies Treated With an Interrupted High-dose Axitinib Schedule
Status: Enrolling
Updated: 3/12/2012
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
City of Hope
mi
from
Duarte, CA
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
Rush University Medical Center
mi
from
Chicago, IL
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
Montefiore Medical Center
mi
from
Bronx, NY
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2012
Sarah Cannon Research Institute
mi
from
Nashville, TN
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2012
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Erlotinib in Treating Patients With a History of Stage I, Stage II, or Stage III Colorectal Cancer or Adenoma
A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon
Status: Enrolling
Updated:  3/13/2012
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Erlotinib in Treating Patients With a History of Stage I, Stage II, or Stage III Colorectal Cancer or Adenoma
A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon
Status: Enrolling
Updated: 3/13/2012
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials
Erlotinib in Treating Patients With a History of Stage I, Stage II, or Stage III Colorectal Cancer or Adenoma
A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon
Status: Enrolling
Updated:  3/13/2012
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
Erlotinib in Treating Patients With a History of Stage I, Stage II, or Stage III Colorectal Cancer or Adenoma
A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon
Status: Enrolling
Updated: 3/13/2012
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Erlotinib in Treating Patients With a History of Stage I, Stage II, or Stage III Colorectal Cancer or Adenoma
A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon
Status: Enrolling
Updated:  3/13/2012
University of Illinois at Chicago Medical Center
mi
from
Chicago, IL
Erlotinib in Treating Patients With a History of Stage I, Stage II, or Stage III Colorectal Cancer or Adenoma
A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon
Status: Enrolling
Updated: 3/13/2012
University of Illinois at Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
A Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of Patients With HER2/Neu+ Breast Cancer Who Have Failed Trastuzumab and Chemotherapy Including a Taxane
Status: Enrolling
Updated:  3/13/2012
Arizona Clinical Research Center
mi
from
Tucson, AZ
APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
A Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of Patients With HER2/Neu+ Breast Cancer Who Have Failed Trastuzumab and Chemotherapy Including a Taxane
Status: Enrolling
Updated: 3/13/2012
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
A Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of Patients With HER2/Neu+ Breast Cancer Who Have Failed Trastuzumab and Chemotherapy Including a Taxane
Status: Enrolling
Updated:  3/13/2012
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
A Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of Patients With HER2/Neu+ Breast Cancer Who Have Failed Trastuzumab and Chemotherapy Including a Taxane
Status: Enrolling
Updated: 3/13/2012
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials